PRF Technologies (PRFX) Convertible Debt (2019 - 2023)

PRF Technologies (PRFX) recorded quarterly Convertible Debt of $478000.0 in Q4 2023, down 91.05% on a QoQ basis from $5.3 million in Q2 2020.

PRF Technologies (PRFX) Convertible Debt (2019 - 2023) Analysis & Trends

PRF Technologies has disclosed Convertible Debt across 3 years of filings, most recently posting $478000.0 for Q4 2023.

  • Quarterly Convertible Debt changed N/A year-over-year to $478000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $478000.0 (changed N/A YoY) and the FY2023 annual result came in at $478000.0, changed N/A from the prior year.
  • Convertible Debt retreated to $478000.0 in Q4 2023, from $5.3 million in the prior quarter.
  • Over five years, Convertible Debt peaked at $5.3 million in Q2 2020 and troughed at $478000.0 in Q4 2023.
  • A 3-year average of $3.4 million and a median of $4.4 million in 2019 frame the typical range for Convertible Debt.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 PRF Technologies 933,081.16 -2.46 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2023 478,000.00
Jun 30, 2020 5.34 Mn
Dec 31, 2019 4.42 Mn